Combination antiarrhythmic drug therapy in a polypill is currently limited in clinical practice due to narrow indications, the need for dose titration, frequent side effects, and lack of mortality benefit.
The development of a polypill containing combination antiarrhythmic therapy is currently not feasible due to safety concerns, the need for individualized dose titration, and a lack of mortality benefit.
In this article, we discuss the feasibility of combination antiarrhythmic drug therapy in the form of a polypill. In our opinion, this type of treatment is currently limited by various factors discussed in this article. Large-sample studies are needed to evaluate the efficacy and safety of different antiarrhythmic drug combinations in patients with atrial fibrillation, as well as supraventricular and ventricular arrhythmias.
Rubanenko et al. (Tue,) conducted a review in Arrhythmias. Combination antiarrhythmic drug therapy (polypill) was evaluated. Combination antiarrhythmic drug therapy in a polypill is currently limited in clinical practice due to narrow indications, the need for dose titration, frequent side effects, and lack of mortality benefit.